Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)

NCT04352400 is registered in ClinicalTrials.gov with University Hospital Padova as lead sponsor.

NCT NCT04352400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04352400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)
Lead sponsor
University Hospital Padova
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 4, 2021
Completion date
December 31, 2024
Enrollment
256 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19